Strong clinical advance perceptions and anticipated displacement of other IgAN-targeted therapies position Voyxact for ...

This episode, titled Positioning Emerging Targeted Therapies in the Evolving IgA Nephropathy Treatment Paradigm, features ...

In the final episode, Assessing Long-Term Renal Outcomes and Kidney Failure Risk Reduction in IgA Nephropathy, the panelists ...

Novartis announced that its investigational drug Vanrafia has successfully demonstrated the ability to slow kidney function decline in adults living with IgA nephropathy (IgAN), a chronic and ...

IgA nephropathy, also known as Berger’s disease, is a progressive, autoimmune, chronic kidney disease that predominantly affects adults between the ages of 20 and 40. It is characterized by the ...

Add Yahoo as a preferred source to see more of our stories on Google. May 11—(StatePoint) IgA nephropathy is a progressive, autoimmune, chronic disease that predominantly affects adults between the ...

Dr Suneel Udani vividly recalls, as a first-year fellow, caring for a patient with IgA nephropathy whose condition deteriorated despite their best efforts, due to the limited treatment options ...

Please provide your email address to receive an email when new articles are posted on . NephCure will have a free, virtual town hall to bring attention to IgA nephropathy. The nonprofit will also ...

Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia (atrasentan).

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We don't know what causes a patient to ...

Immunoglobulin A (IgA) nephropathy is an autoimmune condition that causes inflammation and damage in your kidneys, which may lead to kidney failure over time. IgA nephropathy develops when IgA builds ...